International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

Actions
  • Price (GBX)642.00
  • Today's Change0.00 / 0.00%
  • Shares traded42.02k
  • 1 Year change-4.18%
  • Beta0.1880
Data delayed at least 20 minutes, as of May 17 2024 16:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Aug 31 2023202320222021
ASSETS
Cash And Short Term Investments--01.56
Total Receivables, Net2.93130.90
Total Inventory------
Prepaid expenses0.040.070.04
Other current assets, total------
Total current assets2.97132.50
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments302313345
Note receivable - long term------
Other long term assets------
Total assets305327348
LIABILITIES
Accounts payable------
Accrued expenses1.190.860.58
Notes payable/short-term debt324022
Current portion long-term debt/capital leases------
Other current liabilities, total0.891.201.62
Total current liabilities354224
Total long term debt000
Total debt324022
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities354224
SHAREHOLDERS EQUITY
Common stock101010
Additional paid-in capital303030
Retained earnings (accumulated deficit)230245284
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity270285324
Total liabilities & shareholders' equity305327348
Total common shares outstanding394141
Treasury shares - common primary issue2.070.520
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.